CD4 and non-small cell lung carcinoma: In perioperative NSCLC patients, complete response (CR) cases treated with anlotinib exhibited a reduction in VEGF+ cells and CD4+FoxP3+ Treg cells in the TME, along with an increase in perivascular CD4+ T cells, CD39+CD8+ T cells, and M1 macrophages (40).